Adherence to Surveillance Among Patients With Superficial Bladder Cancer
Open Access
- 16 April 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 95 (8) , 588-597
- https://doi.org/10.1093/jnci/95.8.588
Abstract
Background: Patients diagnosed with superficial bladder cancer who have not undergone total cystectomy are at high risk for recurrence, and bladder surveillance with cystoscopy is recommended for such patients every 3–6 months. We examined the degree to which bladder cancer patients undergo the recommended surveillance procedures and identified patient and primary care provider characteristics associated with nonadherence to these recommendations. Methods: We used information obtained from the Surveillance, Epidemiology, and End Results (SEER) Program–Medicare-linked database to identify 6717 patients aged 65 years or older who were diagnosed with superficial bladder cancer from 1992 through 1996 and who survived for at least 3 years after diagnosis but did not have a total cystectomy. We used information obtained from Medicare claims forms to examine the frequency with which these patients had a surveillance examination of the bladder during each of five contiguous 6-month intervals from month 7 to month 36 following diagnosis. We examined characteristics of patients and their physicians that were associated with low-intensity surveillance (defined as having an examination during fewer than two of the five possible follow-up intervals). Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: Only 40% of the entire cohort had an examination during all five intervals; 1216 patients (18.1%) had low-intensity surveillance. Patient characteristics that were independently associated with low-intensity surveillance were being age 75 years or older (adjusted OR = 1.54, 95% CI = 1.35 to 1.74), nonwhite (adjusted OR = 1.94, 95% CI = 1.57 to 2.40), and having favorable tumor histology (adjusted OR = 0.59, 95% CI = 0.48 to 0.72 for poorly differentiated versus referent well-differentiated tumor grade) and high comorbidity (adjusted OR = 1.72, 95% CI = 1.30 to 2.27). Residence in an urban area or in a census tract with low median income was also associated with low-intensity surveillance. Conclusions: The actual practice of surveillance for patients with superficial bladder cancer differs substantially from the standards recommended in clinical guidelines.Keywords
This publication has 30 references indexed in Scilit:
- Stage Ta-T1 Bladder Cancer: The Relationship Between Findings At First Followup Cystoscopy And Subsequent Recurrence And ProgressionJournal of Urology, 2002
- Does Clinical Evidence Support ICD-9-CM Diagnosis Coding of Complications?Medical Care, 2000
- RE: EMERGENCY AORTORENAL REVASCULARIZATION DURING SALVAGE RETROPERITONEAL LYMPH NODE DISSECTIONJournal of Urology, 2000
- Racial Differences in the Treatment of Early-Stage Lung CancerNew England Journal of Medicine, 1999
- The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year OutcomeJournal of Urology, 1997
- The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 yearsJournal of Urology, 1995
- Superficial Bladder Cancer: Timing of Check Cystoscopies in the First YearBritish Journal of Urology, 1993
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- Accuracy of Diagnostic Coding for Medicare Patients under the Prospective-Payment SystemNew England Journal of Medicine, 1988
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987